Full-Time

Associate Director/Director

Patient Support Services

Updated on 8/21/2026

Mineralys Therapeutics

Mineralys Therapeutics

51-200 employees

Clinical-stage biopharma targeting aldosterone synthesis

Compensation Overview

$205k - $235k/yr

+ Incentive plans

Remote in USA

Remote

Remote within the US, with travel up to 20–25% based on business needs.

Bachelor's, Master's, MBA, PharmD, Associate's

Category
Customer Experience & Support (1)
Required Skills
Data Visualization
CRM
Data Analysis

Get referred to Mineralys Therapeutics

See people who can refer or advise you

Requirements
  • A Bachelor's or Associate degree is required.
  • At least 7 years of experience in patient services, hub operations, affordability programs, field reimbursement, market access, pharmaceutical operations, consulting, or related healthcare services roles is required.
  • Experience supporting, implementing, managing, or optimizing patient support programs and vendor relationships in a pharmaceutical, biotech, specialty pharmacy, hub services, or healthcare services environment is required.
  • Strong understanding of reimbursement processes, pharmacy distribution, payer dynamics, benefits verification, prior authorization, appeals, copay assistance, patient assistance programs, and compliance requirements is required.
  • Demonstrated ability to analyze operational data, identify trends, develop insights, and communicate recommendations to leadership and cross-functional stakeholders is required.
  • Strong project management skills and the ability to manage multiple priorities in a fast-paced, deadline-driven, entrepreneurial environment are required.
  • Excellent communication, writing, presentation, collaboration, and stakeholder management skills are required.
  • Ability to influence without direct authority and drive alignment across functions and external partners is required.
  • Experience managing vendors, timelines, operational issues, service levels, governance routines, and business inputs for budgets or contracts is required.
  • Proficiency with Microsoft Office Suite is required.
  • Ability to travel based on business needs is required.
Responsibilities
  • Support the development and execution of assigned patient access and affordability workstreams, including overall program operations, copay support, and patient support offerings.
  • Monitor post-launch operations, process flows, business rules, readiness materials, and support resources, and recommend refinements based on performance trends, stakeholder feedback, vendor learnings, and evolving business needs.
  • Identify access, affordability, reimbursement, and operational barriers through program data, vendor feedback, field input, and stakeholder discussions, and translate findings into actionable recommendations.
  • Coordinate cross-functional reviews to keep program materials, operating processes, and affordability solutions aligned with brand priorities, compliance expectations, and patient experience objectives.
  • Manage day-to-day activities with patient services vendors, including hub, copay, affordability, data, digital engagement, and related operational partners.
  • Coordinate vendor launch readiness and execution across implementation checkpoints, testing timelines, go-live dependencies, issue resolution, escalation paths, and cross-vendor alignment.
  • Track vendor milestones, dependencies, risks, issue logs, decisions, testing activities, and readiness deliverables for assigned workstreams, and provide updates and recommended next steps to working teams and leadership.
  • Monitor vendor performance against service levels, key performance indicators, quality expectations, business rules, and documented operating procedures, and escalate performance, compliance, budget, or timeline risks with recommended resolutions.
  • Support master service agreement, statement of work, change order, invoice, and budget tracking activities by coordinating business inputs with procurement, legal, finance, compliance, and Patient Services leadership.
  • Own and maintain launch readiness trackers, action items, dependencies, meeting outputs, and operational documentation for assigned Patient Services workstreams.
  • Coordinate with Commercial, Market Access, Data & Analytics, Marketing, Trade, Legal/Compliance, field reimbursement, and vendor teams to identify dependencies, resolve issues, and maintain alignment.
  • Support launch workshops, vendor coordination sessions, readiness reviews, and governance meetings by preparing materials, capturing outputs, and driving follow-up actions.
  • Develop, review, and interpret reports related to program performance, access and reimbursement, affordability utilization, patient engagement, case outcomes, vendor performance, and pharmacy performance.
  • Identify trends, operational gaps, and root causes, and translate findings into concise recommendations for leadership, vendors, and cross-functional partners.
  • Support continuous improvement initiatives that enhance quality, scalability, cycle time, data visibility, compliance execution, and customer experience.
  • Partner with analytics and vendor teams to refine data definitions, reporting cadence, dashboards, and performance review materials.
Desired Qualifications
  • An advanced degree such as an MBA, Master of Public Health, Doctor of Pharmacy, or other relevant graduate degree is preferred.
  • Familiarity with customer relationship management systems, patient services reporting, dashboards, and data analytics tools is preferred.
  • Experience supporting a new product launch or major patient support program implementation is preferred.
  • Experience with cardiovascular, specialty, or retail pharmacy benefit products is preferred.
  • Experience partnering with field reimbursement teams or access account teams to identify payer-related trends and healthcare provider workflow barriers is preferred.
  • Experience preparing leadership-ready materials, vendor business review content, readiness updates, operational dashboards, and issue escalation narratives is preferred.
Mineralys Therapeutics

Mineralys Therapeutics

View

Mineralys Therapeutics develops targeted treatments for diseases driven by dysregulated aldosterone to help lower blood pressure. Its lead drug, lorundrostat, is an oral aldosterone synthase inhibitor that blocks the CYP11B2 enzyme to reduce aldosterone production, with high selectivity over cortisol. It is advancing through late-stage trials (Phase 3) to treat hypertension-related conditions, CKD, and potentially OSA, using funds from its IPO to support trials, manufacturing, and commercialization preparation. By focusing on a selective mechanism that avoids large cortisol disruption, Mineralys differentiates itself from older MRAs and aims to address a large potential market, estimated to exceed $200 billion by 2030.

Company Size

51-200

Company Stage

IPO

Headquarters

Radnor Township, Pennsylvania

Founded

2020

Get referred to Mineralys Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA set lorundrostat's PDUFA for December 22, 2026, keeping launch momentum alive.
  • Q2 2026 CKD data showed a 52.2% placebo-adjusted UACR reduction.
  • Mineralys ended June 30, 2026 with $661.4 million cash and launch readiness.

What critics are saying

  • AstraZeneca's baxdrostat won FDA approval on May 18, 2026, beating lorundrostat to market.
  • Mineralys has one asset; a December 22, 2026 FDA rejection would crush the company.
  • $500 million Pharmakon debt and up to $265 million Tanabe milestones raise launch pressure.

What makes Mineralys Therapeutics unique

  • Lorundrostat is a selective oral aldosterone synthase inhibitor, unlike older MRAs.
  • Mineralys completed six clinical trials and filed an NDA accepted March 9, 2026.
  • Tanabe assigned lorundrostat IP to Mineralys after the June 2026 royalty repurchase.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Remote Work Options

Unlimited Paid Time Off

Flexible Work Hours

Hybrid Work Options

401(k) Company Match

Wellness Program

Mental Health Support

Gym Membership

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Adoption Assistance

Parental Leave

Phone/Internet Stipend

Home Office Stipend

Salary Range?

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-4%

2 year growth

2%
Yahoo Finance
Aug 12th, 2026
Mineralys acquires royalty rights for $200M, secures $500M loan ahead of lorundrostat launch

Mineralys Therapeutics paid $200 million upfront to repurchase future royalty payments from Mitsubishi Tanabe for its hypertension drug lorundrostat, aiming to maximise long-term equity value ahead of commercialisation. The company also secured a $500 million senior secured term loan facility and completed a $150 million equity offering in Q2 2026. New clinical data from the LAUNCH-HTN trial showed lorundrostat achieved a 52% placebo-adjusted reduction in UACR for chronic kidney disease patients. The company is targeting a 22 December 2026 PDUFA date and plans to have its sales force ready before potential approval. R&D expenses rose to $221.4 million in Q2 2026, largely due to the $200 million royalty repurchase payment. Management said market research suggests physicians prefer lorundrostat over competitor baxdrostat by a 2-to-1 margin based on efficacy and safety signals.

Yahoo Finance
Aug 12th, 2026
Mineralys Therapeutics reports $661M cash as Q2 net loss hits $241M on $200M Tanabe buyout

Mineralys Therapeutics reported a net loss of $241.1 million for Q2 2026, compared to $43.3 million in the same period last year, primarily driven by a $200 million upfront payment to Tanabe Pharma to repurchase future royalty payments. The company also faces up to $100 million in milestone payments. Despite the loss, Mineralys maintained a strong cash position of $661.4 million as of 30 June 2026, up from $656.6 million at year-end 2025. The company secured additional funding through a $150 million equity offering and a $500 million senior secured term loan facility. R&D expenses jumped to $221.4 million from $38.3 million year-over-year, whilst G&A expenses rose to $24.7 million from $8.5 million, driven by higher professional fees and personnel costs. The company is preparing for the commercial launch of lorundrostat ahead of the December PDUFA date.

Yahoo Finance
Aug 11th, 2026
Mineralys preps lorundrostat launch as Q2 loss widens on $200M Tanabe payment

Mineralys Therapeutics reported a wider second-quarter loss, largely driven by a $200 million upfront payment related to its amended agreement with Tanabe Pharma Corp. The company is preparing for the commercial launch of lorundrostat, pending FDA approval, with a target decision date of 22 December. Chief Executive Jon Congleton said the company's priorities included launch readiness and evaluating partnership opportunities. Mineralys also appointed Dr Terry Ferguson as chief medical officer, succeeding Dr David Rodman. During the quarter, the company presented clinical data from its Launch-HTN trial, showing statistically meaningful blood-pressure reductions in patients with chronic kidney disease. Formal label discussions with the FDA are expected in October or November.

WPGX Fox 28
Jun 3rd, 2026
Mineralys Therapeutics announces pricing of $150 million underwritten offering of common stock.

Mineralys Therapeutics announces pricing of $150 million underwritten offering of common stock. * 2 hrs ago RADNOR, Pa., June 03, 2026 (GLOBE NEWSWIRE) - Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the pricing of an underwritten offering of 5,660,378 shares of its common stock at a price of $26.50 per share. The aggregate gross proceeds to Mineralys from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $150.0 million. All of the securities to be sold in the offering are to be sold by Mineralys. The offering is expected to close on or about June 4, 2026, subject to the satisfaction of customary closing conditions. BofA Securities, Goldman Sachs & Co. LLC and Evercore ISI are acting as joint book-running managers for the offering. Mineralys intends to use the net proceeds from the offering to fund a portion of the $200.0 million upfront payment for the repurchase of the royalty obligation under its license agreement with Tanabe Pharma Corporation. Earlier today, Mineralys announced entering into a $500 million committed debt facility with funds managed by Pharmakon Advisors, LP. Novo Raises Forecast as Wegovy Pill Fuels Sales The securities described above are being offered by Mineralys pursuant to a shelf registration statement that became automatically effective upon filing with the Securities and Exchange Commission (SEC). A prospectus supplement and accompanying prospectus relating to this offering will be filed with the SEC. When available, copies of the prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: BofA Securities NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, North Carolina 28255-0001 or by email at [email protected]; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, via telephone: (866) 471-2526, via fax: 212-902-9316, or via email: [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200, or by email at [email protected]. Electronic copies of the prospectus supplement and accompanying prospectus will also be available on the website of the SEC at http://www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the completion of the proposed offering and the anticipated use of proceeds therefrom. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Mineralys' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the proposed offering, and the other risks described in Mineralys' filings with the SEC, including under the heading "Risk Factors" in Mineralys' most recent Annual Report on Form 10-K and any subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Mineralys undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Investor Relations Media Relations Melyssa Weible Elixir Health Public Relations Around the web.

wallstreet:online AG
Jun 3rd, 2026
Mineralys raises $650M, buys out lorundrostat royalty for $200M upfront

Mineralys Therapeutics has repurchased its royalty obligations to Tanabe Pharma Corporation for lorundrostat, paying $200 million upfront and up to $100 million upon reaching certain commercial milestones. The deal eliminates all future royalty payments under the existing licence agreement. Concurrently, Mineralys secured a $500 million committed senior secured term loan facility from funds managed by Pharmakon Advisors, with $100 million funded at closing. The company also priced a $150 million common stock offering. Following the transaction, Mineralys' aggregate potential future milestone payments to Tanabe will total up to $265 million, including $100 million in new commercial milestones and $165 million in existing ones. Tanabe will also assign its intellectual property rights for lorundrostat to Mineralys.